Mutual of America Capital Management LLC Sells 2,165 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mutual of America Capital Management LLC reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 51,317 shares of the company's stock after selling 2,165 shares during the quarter. Mutual of America Capital Management LLC owned 0.05% of Neurocrine Biosciences worth $5,676,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Huntington National Bank grew its position in Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after buying an additional 97 shares during the period. GeoWealth Management LLC grew its position in Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after buying an additional 102 shares during the period. Smallwood Wealth Investment Management LLC bought a new stake in Neurocrine Biosciences during the first quarter valued at approximately $34,000. Golden State Wealth Management LLC grew its position in Neurocrine Biosciences by 116.9% during the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company's stock valued at $44,000 after buying an additional 214 shares during the period. Finally, Versant Capital Management Inc grew its position in Neurocrine Biosciences by 404.9% during the first quarter. Versant Capital Management Inc now owns 409 shares of the company's stock valued at $45,000 after buying an additional 328 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Jude Onyia sold 59,819 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the sale, the insider owned 18,289 shares of the company's stock, valued at approximately $2,385,982.94. This represents a 76.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kevin Charles Gorman sold 9,613 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the transaction, the director directly owned 514,596 shares of the company's stock, valued at approximately $61,947,066.48. This represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 120,251 shares of company stock worth $14,978,602 in the last ninety days. Company insiders own 4.80% of the company's stock.

Neurocrine Biosciences Stock Down 0.2%

Neurocrine Biosciences stock traded down $0.30 during mid-day trading on Friday, reaching $133.81. 108,691 shares of the company's stock traded hands, compared to its average volume of 1,142,446. The company has a market cap of $13.24 billion, a price-to-earnings ratio of 45.33, a PEG ratio of 1.37 and a beta of 0.24. The stock has a 50 day moving average of $125.18 and a two-hundred day moving average of $121.53. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. Neurocrine Biosciences's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.20 EPS. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on NBIX. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a research report on Thursday, July 10th. They set a "buy" rating and a $182.00 target price for the company. Canaccord Genuity Group lifted their price target on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Guggenheim lifted their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, UBS Group lifted their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a report on Wednesday, July 9th. Three equities research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.